A new treatment to improve ovarian cancer therapy by blocking DNA repair mechanisms
Official title: The SIK2 Inhibitor GRN-300 enhances PARP Inhibitor sensitivity and overcomes resistance by blocking homologous recombination (HR) DNA repair in ovarian cancer
Funded at University of Tx Md Anderson Can Ctr · NIH-10993526 · Data updated 2026-11-12
This study is looking at a new drug called GRN-300 to see if it can make existing ovarian cancer treatments work better, especially for patients whose cancer has become resistant to standard therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 19, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $177,085 |
| NIH project number | 3P50CA281701-02S1 |
| Project ID | NIH-10993526 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women diagnosed with ovarian cancer, especially those who have shown resistance to standard treatments like carboplatin and paclitaxel.
✕Less likely to help
Patients with early-stage ovarian cancer who have not yet undergone treatment may not benefit from this research.
What this research studies
This research investigates the use of a drug called GRN-300, which inhibits a specific protein (SIK2) to enhance the effectiveness of existing ovarian cancer treatments like carboplatin and paclitaxel. The study aims to determine the best dose of GRN-300 when used alone and in combination with these therapies. It also explores how GRN-300 can make ovarian cancer cells more sensitive to another treatment called olaparib, particularly in cases where the cancer has developed resistance to standard therapies. By blocking certain DNA repair processes in cancer cells, this approach hopes to improve treatment outcomes for patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for ovarian cancer patients, particularly those who have become resistant to current therapies.
How similar studies have gone: Previous research has shown promising results with similar approaches in enhancing treatment sensitivity in cancer therapies, indicating potential for success in this study.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Sood, Anil K — University of Tx Md Anderson Can Ctr
- Study coordinator: Sood, Anil K
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.